Exact Mass: 617.3047252

Penitrem F

C37H44ClNO5 (617.2908)

Rotigaptide

C28H39N7O9 (617.2809)

PC(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C30H52NO10P (617.3329)

PC(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0)

C30H52NO10P (617.3329)

PC(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C30H52NO10P (617.3329)

PC(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0)

C30H52NO10P (617.3329)

PC(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C30H52NO10P (617.3329)

PC(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0)

C30H52NO10P (617.3329)

PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

Spiroidesin

C35H43N3O7 (617.3101)

FT-0774565

C36H43NO8 (617.2989)

6-benzylamino-9-(glucosylribosyl)purine

C30H43N5O9 (617.3061)

shearinine C

C37H47NO7 (617.3352)

barbatellarine B

C35H39NO9 (617.2625)

ever-1

C32H43NO11 (617.2836)

penitremone B

C37H47NO7 (617.3352)

8-Deacetylyunaconitine

C33H47NO10 (617.32)

Hypaconitine

C33H47NO10 (617.32)

Glu Lys Ile Asp Asn

C25H43N7O11 (617.302)

Leu Trp Asn Gly Asp

C28H39N7O9 (617.2809)

Glu Glu Gly Gln Arg

C23H39N9O11 (617.2769)

Leu Gly His Phe Met

C29H43N7O6S (617.2995)

Leu Ser Leu Glu Glu

C27H47N5O11 (617.3272)

Lys Ile Asp Asn Glu

C25H43N7O11 (617.302)

Glu Glu Leu Ile Thr

C27H47N5O11 (617.3272)

Ala Arg Trp Trp

C31H39N9O5 (617.3074)

Ala Trp Arg Trp

C31H39N9O5 (617.3074)

Ala Trp Trp Arg

C31H39N9O5 (617.3074)

Glu Phe His Trp

C31H35N7O7 (617.2598)

Glu Phe Trp His

C31H35N7O7 (617.2598)

Glu His Phe Trp

C31H35N7O7 (617.2598)

Glu His Trp Phe

C31H35N7O7 (617.2598)

Glu Lys Arg Trp

C28H43N9O7 (617.3285)

Glu Lys Trp Arg

C28H43N9O7 (617.3285)

Glu Gln Arg Trp

C27H39N9O8 (617.2921)

Glu Gln Trp Arg

C27H39N9O8 (617.2921)

Glu Arg Lys Trp

C28H43N9O7 (617.3285)

Glu Arg Gln Trp

C27H39N9O8 (617.2921)

Glu Arg Trp Lys

C28H43N9O7 (617.3285)

Glu Arg Trp Gln

C27H39N9O8 (617.2921)

Glu Trp Phe His

C31H35N7O7 (617.2598)

Glu Trp His Phe

C31H35N7O7 (617.2598)

Glu Trp Lys Arg

C28H43N9O7 (617.3285)

Glu Trp Gln Arg

C27H39N9O8 (617.2921)

Glu Trp Arg Lys

C28H43N9O7 (617.3285)

Glu Trp Arg Gln

C27H39N9O8 (617.2921)

Phe Glu His Trp

C31H35N7O7 (617.2598)

Phe Glu Trp His

C31H35N7O7 (617.2598)

Phe His Glu Trp

C31H35N7O7 (617.2598)

Phe His Trp Glu

C31H35N7O7 (617.2598)

Phe Trp Glu His

C31H35N7O7 (617.2598)

Phe Trp His Glu

C31H35N7O7 (617.2598)

His Glu Phe Trp

C31H35N7O7 (617.2598)

His Glu Trp Phe

C31H35N7O7 (617.2598)

His Phe Glu Trp

C31H35N7O7 (617.2598)

His Phe Trp Glu

C31H35N7O7 (617.2598)

His Ile Trp Tyr

C32H39N7O6 (617.2962)

His Ile Tyr Trp

C32H39N7O6 (617.2962)

His Leu Trp Tyr

C32H39N7O6 (617.2962)

His Leu Tyr Trp

C32H39N7O6 (617.2962)

His Trp Glu Phe

C31H35N7O7 (617.2598)

His Trp Phe Glu

C31H35N7O7 (617.2598)

His Trp Ile Tyr

C32H39N7O6 (617.2962)

His Trp Leu Tyr

C32H39N7O6 (617.2962)

His Trp Tyr Ile

C32H39N7O6 (617.2962)

His Trp Tyr Leu

C32H39N7O6 (617.2962)

His Tyr Ile Trp

C32H39N7O6 (617.2962)

His Tyr Leu Trp

C32H39N7O6 (617.2962)

His Tyr Trp Ile

C32H39N7O6 (617.2962)

His Tyr Trp Leu

C32H39N7O6 (617.2962)

Ile His Trp Tyr

C32H39N7O6 (617.2962)

Ile His Tyr Trp

C32H39N7O6 (617.2962)

Ile Asn Trp Trp

C32H39N7O6 (617.2962)

Ile Trp His Tyr

C32H39N7O6 (617.2962)

Ile Trp Asn Trp

C32H39N7O6 (617.2962)

Ile Trp Trp Asn

C32H39N7O6 (617.2962)

Ile Trp Tyr His

C32H39N7O6 (617.2962)

Ile Tyr His Trp

C32H39N7O6 (617.2962)

Ile Tyr Trp His

C32H39N7O6 (617.2962)

Lys Glu Arg Trp

C28H43N9O7 (617.3285)

Lys Glu Trp Arg

C28H43N9O7 (617.3285)

Lys Arg Glu Trp

C28H43N9O7 (617.3285)

Lys Arg Trp Glu

C28H43N9O7 (617.3285)

Lys Val Trp Trp

C33H43N7O5 (617.3326)

Lys Trp Glu Arg

C28H43N9O7 (617.3285)

Lys Trp Arg Glu

C28H43N9O7 (617.3285)

Lys Trp Val Trp

C33H43N7O5 (617.3326)

Lys Trp Trp Val

C33H43N7O5 (617.3326)

Leu His Trp Tyr

C32H39N7O6 (617.2962)

Leu His Tyr Trp

C32H39N7O6 (617.2962)

Leu Asn Trp Trp

C32H39N7O6 (617.2962)

Leu Trp His Tyr

C32H39N7O6 (617.2962)

Leu Trp Asn Trp

C32H39N7O6 (617.2962)

Leu Trp Trp Asn

C32H39N7O6 (617.2962)

Leu Trp Tyr His

C32H39N7O6 (617.2962)

Leu Tyr His Trp

C32H39N7O6 (617.2962)

Leu Tyr Trp His

C32H39N7O6 (617.2962)

Met Arg Arg Arg

C23H47N13O5S (617.3544)

Asn Ile Trp Trp

C32H39N7O6 (617.2962)

Asn Leu Trp Trp

C32H39N7O6 (617.2962)

Asn Trp Ile Trp

C32H39N7O6 (617.2962)

Asn Trp Leu Trp

C32H39N7O6 (617.2962)

Asn Trp Trp Ile

C32H39N7O6 (617.2962)

Asn Trp Trp Leu

C32H39N7O6 (617.2962)

Gln Glu Arg Trp

C27H39N9O8 (617.2921)

Gln Glu Trp Arg

C27H39N9O8 (617.2921)

Gln Arg Glu Trp

C27H39N9O8 (617.2921)

Gln Arg Trp Glu

C27H39N9O8 (617.2921)

Gln Val Trp Trp

C32H39N7O6 (617.2962)

Gln Trp Glu Arg

C27H39N9O8 (617.2921)

Gln Trp Arg Glu

C27H39N9O8 (617.2921)

Gln Trp Val Trp

C32H39N7O6 (617.2962)

Gln Trp Trp Val

C32H39N7O6 (617.2962)

Arg Ala Trp Trp

C31H39N9O5 (617.3074)

Arg Glu Lys Trp

C28H43N9O7 (617.3285)

Arg Glu Gln Trp

C27H39N9O8 (617.2921)

Arg Glu Trp Lys

C28H43N9O7 (617.3285)

Arg Glu Trp Gln

C27H39N9O8 (617.2921)

Arg Lys Glu Trp

C28H43N9O7 (617.3285)

Arg Lys Trp Glu

C28H43N9O7 (617.3285)

Arg Met Arg Arg

C23H47N13O5S (617.3544)

Arg Gln Glu Trp

C27H39N9O8 (617.2921)

Arg Gln Trp Glu

C27H39N9O8 (617.2921)

Arg Arg Met Arg

C23H47N13O5S (617.3544)

Arg Arg Arg Met

C23H47N13O5S (617.3544)

Arg Arg Thr Trp

C27H43N11O6 (617.3398)

Arg Arg Trp Thr

C27H43N11O6 (617.3398)

Arg Thr Arg Trp

C27H43N11O6 (617.3398)

Arg Thr Trp Arg

C27H43N11O6 (617.3398)

Arg Trp Ala Trp

C31H39N9O5 (617.3074)

Arg Trp Glu Lys

C28H43N9O7 (617.3285)

Arg Trp Glu Gln

C27H39N9O8 (617.2921)

Arg Trp Lys Glu

C28H43N9O7 (617.3285)

Arg Trp Gln Glu

C27H39N9O8 (617.2921)

Arg Trp Arg Thr

C27H43N11O6 (617.3398)

Arg Trp Thr Arg

C27H43N11O6 (617.3398)

Arg Trp Trp Ala

C31H39N9O5 (617.3074)

Thr Arg Arg Trp

C27H43N11O6 (617.3398)

Thr Arg Trp Arg

C27H43N11O6 (617.3398)

Thr Trp Arg Arg

C27H43N11O6 (617.3398)

Val Lys Trp Trp

C33H43N7O5 (617.3326)

Val Gln Trp Trp

C32H39N7O6 (617.2962)

Val Trp Lys Trp

C33H43N7O5 (617.3326)

Val Trp Gln Trp

C32H39N7O6 (617.2962)

Val Trp Trp Lys

C33H43N7O5 (617.3326)

Val Trp Trp Gln

C32H39N7O6 (617.2962)

Trp Ala Arg Trp

C31H39N9O5 (617.3074)

Trp Ala Trp Arg

C31H39N9O5 (617.3074)

Trp Glu Phe His

C31H35N7O7 (617.2598)

Trp Glu His Phe

C31H35N7O7 (617.2598)

Trp Glu Lys Arg

C28H43N9O7 (617.3285)

Trp Glu Gln Arg

C27H39N9O8 (617.2921)

Trp Glu Arg Lys

C28H43N9O7 (617.3285)

Trp Glu Arg Gln

C27H39N9O8 (617.2921)

Trp Phe Glu His

C31H35N7O7 (617.2598)

Trp Phe His Glu

C31H35N7O7 (617.2598)

Trp His Glu Phe

C31H35N7O7 (617.2598)

Trp His Phe Glu

C31H35N7O7 (617.2598)

Trp His Ile Tyr

C32H39N7O6 (617.2962)

Trp His Leu Tyr

C32H39N7O6 (617.2962)

Trp His Tyr Ile

C32H39N7O6 (617.2962)

Trp His Tyr Leu

C32H39N7O6 (617.2962)

Trp Ile His Tyr

C32H39N7O6 (617.2962)

Trp Ile Asn Trp

C32H39N7O6 (617.2962)

Trp Ile Trp Asn

C32H39N7O6 (617.2962)

Trp Ile Tyr His

C32H39N7O6 (617.2962)

Trp Lys Glu Arg

C28H43N9O7 (617.3285)

Trp Lys Arg Glu

C28H43N9O7 (617.3285)

Trp Lys Val Trp

C33H43N7O5 (617.3326)

Trp Lys Trp Val

C33H43N7O5 (617.3326)

Trp Leu His Tyr

C32H39N7O6 (617.2962)

Trp Leu Asn Trp

C32H39N7O6 (617.2962)

Trp Leu Trp Asn

C32H39N7O6 (617.2962)

Trp Leu Tyr His

C32H39N7O6 (617.2962)

Trp Asn Ile Trp

C32H39N7O6 (617.2962)

Trp Asn Leu Trp

C32H39N7O6 (617.2962)

Trp Asn Trp Ile

C32H39N7O6 (617.2962)

Trp Asn Trp Leu

C32H39N7O6 (617.2962)

Trp Gln Glu Arg

C27H39N9O8 (617.2921)

Trp Gln Arg Glu

C27H39N9O8 (617.2921)

Trp Gln Val Trp

C32H39N7O6 (617.2962)

Trp Gln Trp Val

C32H39N7O6 (617.2962)

Trp Arg Ala Trp

C31H39N9O5 (617.3074)

Trp Arg Glu Lys

C28H43N9O7 (617.3285)

Trp Arg Glu Gln

C27H39N9O8 (617.2921)

Trp Arg Lys Glu

C28H43N9O7 (617.3285)

Trp Arg Gln Glu

C27H39N9O8 (617.2921)

Trp Arg Arg Thr

C27H43N11O6 (617.3398)

Trp Arg Thr Arg

C27H43N11O6 (617.3398)

Trp Arg Trp Ala

C31H39N9O5 (617.3074)

Trp Thr Arg Arg

C27H43N11O6 (617.3398)

Trp Val Lys Trp

C33H43N7O5 (617.3326)

Trp Val Gln Trp

C32H39N7O6 (617.2962)

Trp Val Trp Lys

C33H43N7O5 (617.3326)

Trp Val Trp Gln

C32H39N7O6 (617.2962)

Trp Trp Ala Arg

C31H39N9O5 (617.3074)

Trp Trp Ile Asn

C32H39N7O6 (617.2962)

Trp Trp Lys Val

C33H43N7O5 (617.3326)

Trp Trp Leu Asn

C32H39N7O6 (617.2962)

Trp Trp Asn Ile

C32H39N7O6 (617.2962)

Trp Trp Asn Leu

C32H39N7O6 (617.2962)

Trp Trp Gln Val

C32H39N7O6 (617.2962)

Trp Trp Arg Ala

C31H39N9O5 (617.3074)

Trp Trp Val Lys

C33H43N7O5 (617.3326)

Trp Trp Val Gln

C32H39N7O6 (617.2962)

Trp Tyr His Ile

C32H39N7O6 (617.2962)

Trp Tyr His Leu

C32H39N7O6 (617.2962)

Trp Tyr Ile His

C32H39N7O6 (617.2962)

Trp Tyr Leu His

C32H39N7O6 (617.2962)

Tyr His Ile Trp

C32H39N7O6 (617.2962)

Tyr His Leu Trp

C32H39N7O6 (617.2962)

Tyr His Trp Ile

C32H39N7O6 (617.2962)

Tyr His Trp Leu

C32H39N7O6 (617.2962)

Tyr Ile His Trp

C32H39N7O6 (617.2962)

Tyr Ile Trp His

C32H39N7O6 (617.2962)

Tyr Leu His Trp

C32H39N7O6 (617.2962)

Tyr Leu Trp His

C32H39N7O6 (617.2962)

Tyr Trp His Ile

C32H39N7O6 (617.2962)

Tyr Trp His Leu

C32H39N7O6 (617.2962)

Tyr Trp Ile His

C32H39N7O6 (617.2962)

Tyr Trp Leu His

C32H39N7O6 (617.2962)

EKIDN

C25H43N7O11 (617.302)

KIDNE

C25H43N7O11 (617.302)

EEGQR

C23H39N9O11 (617.2769)

NRESL

C24H43N9O10 (617.3133)

DELNQ

C24H39N7O12 (617.2657)

OKOHA-PE

C30H52NO10P (617.3329)

fmoc-tyr(malonyl-di-otbu)-oh

C35H39NO9 (617.2625)

Rotigaptide

C28H39N7O9 (617.2809)

C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent

Benzeneacetamide, N-((4-hydroxy(1,1-biphenyl)-3-yl)methyl)-3-(2-(((2R)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-2-methylpropyl)-

C34H39N3O6S (617.2559)

5-[[4-[5-[[4-[5-[Acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylazanium;iron

C25H49FeN6O8+ (617.2961)

PC(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C30H52NO10P (617.3329)

PC(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0)

C30H52NO10P (617.3329)

PC(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C30H52NO10P (617.3329)

PC(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0)

C30H52NO10P (617.3329)

PC(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C30H52NO10P (617.3329)

PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0)

C30H52NO10P (617.3329)

WLL-vs

C31H47N5O6S (617.3247)

4-[3-[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[(4-methyl-1-piperazinyl)-oxomethyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]-N,N-dimethylbenzamide

C34H43N5O4S (617.3036)

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213)

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea

C31H38F3N5O5 (617.2825)

N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea

C31H38F3N5O5 (617.2825)

N-[(3S,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea

C31H38F3N5O5 (617.2825)

N-[(3S,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

4-[3-[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[(4-methyl-1-piperazinyl)-oxomethyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]-N,N-dimethylbenzamide

C34H43N5O4S (617.3036)

3-[3-[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[(4-methyl-1-piperazinyl)-oxomethyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]-N,N-dimethylbenzamide

C34H43N5O4S (617.3036)

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213)

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213)

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213)

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213)

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213)

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213)

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea

C31H38F3N5O5 (617.2825)

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea

C31H38F3N5O5 (617.2825)

N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea

C31H38F3N5O5 (617.2825)

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea

C31H38F3N5O5 (617.2825)

N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

N-[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213)

3-[3-[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[(4-methyl-1-piperazinyl)-oxomethyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]-N,N-dimethylbenzamide

C34H43N5O4S (617.3036)

Lnaps 6:0/N-18:3

C30H52NO10P (617.3329)

Lnaps 2:0/N-22:3

C30H52NO10P (617.3329)

Lnaps 8:0/N-16:3

C30H52NO10P (617.3329)

Lnaps 16:3/N-8:0

C30H52NO10P (617.3329)

Lnaps 22:3/N-2:0

C30H52NO10P (617.3329)

Lnaps 18:3/N-6:0

C30H52NO10P (617.3329)

Lnaps 4:0/N-20:3

C30H52NO10P (617.3329)

Lnaps 20:3/N-4:0

C30H52NO10P (617.3329)

2-amino-3-[[3-butanoyloxy-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H52NO10P (617.3329)

2-amino-3-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H52NO10P (617.3329)

2-amino-3-[[3-hexanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H52NO10P (617.3329)

3-[[3-acetyloxy-2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxy-2-aminopropanoic acid

C30H52NO10P (617.3329)

PC 14:1/8:3;O2

C30H52NO10P (617.3329)

PC 18:3/4:1;O2

C30H52NO10P (617.3329)

PC 22:4;O2

C30H52NO10P (617.3329)

PE O-25:5;O3

C30H52NO10P (617.3329)

PE P-18:1/7:3;O3

C30H52NO10P (617.3329)

PE 16:0/9:4;O2

C30H52NO10P (617.3329)

PE 18:1/7:3;O2

C30H52NO10P (617.3329)

PE 18:2/7:2;O2

C30H52NO10P (617.3329)

PE 20:3/5:1;O2

C30H52NO10P (617.3329)

LNAPS 23:4;O

C29H48NO11P (617.2965)

LNAPS 24:3

C30H52NO10P (617.3329)

PS O-23:5;O2

C29H48NO11P (617.2965)

PS O-24:4;O

C30H52NO10P (617.3329)

PS P-16:0/8:3;O

C30H52NO10P (617.3329)

PS P-16:1/7:3;O2

C29H48NO11P (617.2965)

PS P-18:1/6:2;O

C30H52NO10P (617.3329)

PS 16:1/7:3;O

C29H48NO11P (617.2965)

PS 18:3/5:1;O

C29H48NO11P (617.2965)

PS 18:4/4:1;O2

C28H44NO12P (617.2601)

PS 22:5;O2

C28H44NO12P (617.2601)

PS 23:4;O

C29H48NO11P (617.2965)

PS 20:2/4:1

C30H52NO10P (617.3329)

PS 20:3/4:0

C30H52NO10P (617.3329)

PS 24:3

C30H52NO10P (617.3329)

ST 21:1;O8;HexNAc

C29H47NO13 (617.3047)

ST 22:0;O7;HexNAc

C30H51NO12 (617.3411)

ST 24:6;O6;HexNAc

C32H43NO11 (617.2836)

ST 25:5;O5;HexNAc

C33H47NO10 (617.32)

ST 28:2;O7;Tau

C30H51NO10S (617.3234)

Cyclo(RADfK)

C28H43N9O7 (617.3285)

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

21-chloro-15,16,33,33-tetramethyl-24-methylidene-10-(prop-1-en-2-yl)-7,11,32-trioxa-18-azadecacyclo[25.4.2.0²,¹⁶.0⁵,¹⁵.0⁶,⁸.0⁶,¹².0¹⁷,³¹.0¹⁹,³⁰.0²²,²⁹.0²⁵,²⁸]tritriaconta-17(31),19,21,29-tetraene-5,9-diol

C37H44ClNO5 (617.2908)

(4r,5r,6s,7s,8r,18s)-8-(acetyloxy)-5,7,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl benzoate

C32H43NO11 (617.2836)

3-[(2s)-4-[(2e,4e,6s)-6-[(2s,5r,6r)-1,6-dimethyl-8,9-dioxaspiro[bicyclo[3.3.1]nonane-2,2'-oxiran]-3-en-7-yl]-4-methylhepta-2,4-dienoyl]-1-(5-hydroxy-6-methyloxan-2-yl)-3,5-dioxopyrrolidin-2-yl]propanoic acid; ethane

C33H47NO10 (617.32)

(1s,19s,22s,26r,31r)-2,22-dihydroxy-26-(2-hydroxypropan-2-yl)-1,9,9,11,11,31-hexamethyl-10,27-dioxa-3-azaheptacyclo[17.12.0.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹².0²²,³¹.0²³,²⁸]hentriaconta-2,4(16),5,7(12),14,23-hexaene-17,25-dione

C37H47NO7 (617.3352)

14-benzoyl-8-o-methyl-aconine i

C33H47NO10 (617.32)

{"Ingredient_id": "HBIN001369","Ingredient_name": "14-benzoyl-8-o-methyl-aconine i","Alias": "NA","Ingredient_formula": "C33H47NO10","Ingredient_Smile": "CCN1CC2(C(CC(C34C2C(C(C31)C5(C6C4CC(C6OC(=O)C7=CC=CC=C7)(C(C5O)OC)O)OC)OC)OC)O)COC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2248","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

8-deacetylyunaconitine

C33H47NO10 (617.32)

{"Ingredient_id": "HBIN013693","Ingredient_name": "8-deacetylyunaconitine","Alias": "NA","Ingredient_formula": "C33H47NO10","Ingredient_Smile": "CCN1CC2(C(CC(C34C2C(C(C31)C5(CC(C6(CC4C5C6OC(=O)C7=CC=C(C=C7)OC)O)OC)O)OC)OC)O)COC","Ingredient_weight": "617.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4791","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "137706281","DrugBank_id": "NA"}

n-benzyl-9-[(2r,3r,4r,5r)-3,4-dimethoxy-5-({[(2r,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}methyl)oxolan-2-yl]-n-methylpurin-6-amine

C30H43N5O9 (617.3061)

(1s,2r,5s,6s,8r,9s,10r,12s,15r,16s,25s,27s,28s)-21-chloro-15,16,33,33-tetramethyl-24-methylidene-10-(prop-1-en-2-yl)-7,11,32-trioxa-18-azadecacyclo[25.4.2.0²,¹⁶.0⁵,¹⁵.0⁶,⁸.0⁶,¹².0¹⁷,³¹.0¹⁹,³⁰.0²²,²⁹.0²⁵,²⁸]tritriaconta-17(31),19,21,29-tetraene-5,9-diol

C37H44ClNO5 (617.2908)

4-[1-(acetyloxy)-2-(5-oxo-2h-furan-3-yl)ethyl]-2-(benzoyloxy)-3-hydroxy-3,4,8,8a-tetramethyl-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl pyridine-3-carboxylate

C35H39NO9 (617.2625)

(1s)-1-[(1r,3ar,7s,9ar,9br,11r,11ar)-1,3a,3b,7-tetrahydroxy-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C36H43NO8 (617.2989)

(1s,3r,5s,7r,9s,10r,12r,14r,15s,18r,19s,22s,23r)-4',10-dihydroxy-22-(hydroxymethyl)-7,18-dimethyl-19-(5-oxo-2h-furan-3-yl)-5'h-4,6,11-trioxaspiro[hexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosane-9,2'-[1,3]thiazole]-14-carbaldehyde

C32H43NO9S (617.2658)

1-[(1s,3ar,3bs,7s,9ar,11r,11ar)-1,3a,3b,7-tetrahydroxy-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C36H43NO8 (617.2989)

(1s,2r,3r,4r,5s,6s,8r,9r,10r,13r,14r,16s,17s,18r)-11-ethyl-5,8,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

C33H47NO10 (617.32)

(1s,2r,5s,6r,8s,9r,10r,12r,15s,16r,25r,27s,28s)-21-chloro-15,16,33,33-tetramethyl-24-methylidene-10-(prop-1-en-2-yl)-7,11,32-trioxa-18-azadecacyclo[25.4.2.0²,¹⁶.0⁵,¹⁵.0⁶,⁸.0⁶,¹².0¹⁷,³¹.0¹⁹,³⁰.0²²,²⁹.0²⁵,²⁸]tritriaconta-17(31),19,21,29-tetraene-5,9-diol

C37H44ClNO5 (617.2908)

2-{[1-hydroxy-2-({1-hydroxy-2-[(1-hydroxyhexylidene)amino]-4-(4-hydroxyphenyl)butylidene}amino)-4-(4-hydroxyphenyl)butylidene]amino}-3-phenylpropanoic acid

C35H43N3O7 (617.3101)

n-benzyl-9-[3,4-dimethoxy-5-({[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}methyl)oxolan-2-yl]-n-methylpurin-6-amine

C30H43N5O9 (617.3061)

(1s,2r,3r,4r,5s,6s,8r,10r,13r,14r,16s,17s)-11-ethyl-5,8,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

C33H47NO10 (617.32)

11-ethyl-5,8,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

C33H47NO10 (617.32)

2,22-dihydroxy-26-(2-hydroxypropan-2-yl)-1,9,9,11,11,31-hexamethyl-10,27-dioxa-3-azaheptacyclo[17.12.0.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹².0²²,³¹.0²³,²⁸]hentriaconta-2,4(16),5,7,14,23-hexaene-17,25-dione

C37H47NO7 (617.3352)

(1r,12r,19r,22r,26s,28r,31s)-2,22-dihydroxy-26-(2-hydroxypropan-2-yl)-1,9,9,11,11,31-hexamethyl-10,27-dioxa-3-azaheptacyclo[17.12.0.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹².0²²,³¹.0²³,²⁸]hentriaconta-2,4(16),5,7,14,23-hexaene-17,25-dione

C37H47NO7 (617.3352)

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-1,3a,3b,7-tetrahydroxy-9a,11a-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C36H43NO8 (617.2989)

1-{1,3a,3b,7-tetrahydroxy-9a,11a-dimethyl-11-[(3-phenylprop-2-enoyl)oxy]-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl pyridine-3-carboxylate

C36H43NO8 (617.2989)

(1r,2s,3r,4s,4as,8ar)-4-[(1s)-1-(acetyloxy)-2-(5-oxo-2h-furan-3-yl)ethyl]-2-(benzoyloxy)-3-hydroxy-3,4,8,8a-tetramethyl-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl pyridine-3-carboxylate

C35H39NO9 (617.2625)

(1s,19s,22s,26r,28s,31r)-2,22-dihydroxy-26-(2-hydroxypropan-2-yl)-1,9,9,11,11,31-hexamethyl-10,27-dioxa-3-azaheptacyclo[17.12.0.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹².0²²,³¹.0²³,²⁸]hentriaconta-2,4(16),5,7,14,23-hexaene-17,25-dione

C37H47NO7 (617.3352)

2,22-dihydroxy-26-(2-hydroxypropan-2-yl)-1,9,9,11,11,31-hexamethyl-10,27-dioxa-3-azaheptacyclo[17.12.0.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹².0²²,³¹.0²³,²⁸]hentriaconta-2,4(16),5,7(12),14,23-hexaene-17,25-dione

C37H47NO7 (617.3352)

n-{2-[hydroxy({3-[(2r,4r)-1-[(3r)-1-hydroxy-2-oxopiperidin-3-yl]-2,3-dimethyl-5-oxoimidazolidin-4-yl]propyl})carbamoyl]ethyl}-2-({hydroxy[(4s)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazol-4-yl]methylidene}amino)ethanimidic acid

C28H39N7O9 (617.2809)

(2r)-2-{[(2s)-1-hydroxy-2-{[(2r)-1-hydroxy-2-[(1-hydroxyhexylidene)amino]-4-(4-hydroxyphenyl)butylidene]amino}-4-(4-hydroxyphenyl)butylidene]amino}-3-phenylpropanoic acid

C35H43N3O7 (617.3101)